Side by side

1. 1.In laboratory fat cells, the fragment stimulates lipolysis — the breakdown of stored fat into fatty acids.
2. 2.It is designed to keep growth hormone's fat effects without raising IGF-1 or affecting blood glucose, based on animal data.
3. 3.That separation is the central claim, and it is precisely what the human trials failed to translate into weight loss.
4. 4.The parent hormone's fat effects depend on much more than this short region, which may explain the gap between laboratory and human results.

• Obesity (phase 2 and phase 3 trials, results negative)
• Lipodystrophy (studied, not approved)
• Cartilage repair in laboratory and animal models
• Muscle wasting in small early studies

• No statistically significant weight loss versus placebo in the completed human trials
• Lipolysis in isolated fat cells
• Marketed claims of 'fat burning without hormone effects' are not supported by the human trial results
• Long-term body-composition effects in humans are unestablished

• Reported as generally well tolerated in the trials
• Mild gastrointestinal symptoms in some participants
• No long-term safety data
• Injectable products sold online are unregulated and of unknown purity

Research context only — no approved protocol and no legitimate product. Trials used oral doses in the 1–3 mg per day range for 12–24 weeks, and the primary weight-loss endpoints were not met. This is a record of what was studied, not a recommendation.

Research context only